Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
The European Respiratory Journal|September 1, 2009
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaA Scherpereel, P Astoul, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743S Peters, A Scherpereel, R Cornelissen, et al.
ESMO Open|July 26, 2024
Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasmsN Benzerdjeb, P Dartigues, V Kepenekian, et al.
The European Respiratory Journal|July 9, 2011
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendationsT Berghmans, F Pasleau, M Paesmans, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
Pageof 5